What H.R 7987 Would Unleash On The Cannabis Sector…

U.S. Cannabis Uplisting Could Trigger a Multi-Billion Dollar Repricing Event

The introduction of H.R. 7987 could mark a turning point for U.S. cannabis stocks—one that fundamentally reshapes how institutional capital interacts with the sector. By proposing a federal safe harbor that allows major exchanges to list cannabis-related businesses, the bill directly targets one of the industry’s biggest constraints: access to U.S. capital markets. If enacted, this is not simply regulatory progress; it is a structural market catalyst.

Today, leading U.S. multi-state operators (MSOs) such as $GTBIF, $TCNNF, and $CURLF remain largely restricted to over-the-counter markets or Canadian exchanges. This limitation suppresses institutional ownership, reduces liquidity, and contributes to persistent valuation discounts relative to global peers. In many cases, U.S. cannabis companies trade at roughly 4 to 8 times EBITDA, while comparable consumer and healthcare companies trade at multiples closer to 12 to 25 times. The gap is not driven by operational performance, but by structural constraints tied to federal policy.

Uplisting would immediately begin to close that gap by unlocking institutional capital. Pension funds, mutual funds, index funds, and large asset managers are often prohibited from investing in OTC securities. Once these companies are eligible for listing on major U.S. exchanges, they become accessible to significantly larger pools of capital. This shift alone could dramatically increase demand for cannabis equities and initiate a broad re-rating across the sector.

Liquidity would also improve materially. Exchange-listed securities benefit from tighter bid-ask spreads, higher trading volumes, and deeper order books. For cannabis companies, this would reduce volatility while improving price discovery and enabling more efficient capital formation. Access to lower-cost capital is especially important in an industry that remains capital-intensive and growth-driven. As financing conditions improve, companies can reinvest more efficiently into expansion, operations, and consolidation.

The most significant impact, however, may come from multiple expansion. If U.S. MSOs re-rate from approximately 6 times EBITDA to 12 times EBITDA, valuations could effectively double without any change in underlying business performance. This type of repricing has been observed in other sectors that transitioned from restricted to institutionally accessible, including online betting, crypto-adjacent equities, and emerging technology platforms following index inclusion.

At the same time, the current market structure creates the conditions for a potential short squeeze and rapid float rotation. Cannabis equities today are often thinly traded, heavily shorted, and dominated by retail investors. Uplisting introduces institutional bid support, professional market-making, and significantly higher liquidity. As demand increases and float turns over more rapidly, short positions may be forced to cover into rising prices, accelerating upward momentum and intensifying the repricing dynamic.

For now, one of the only liquid ways to gain exposure to U.S. cannabis operators is through the ETF $MSOS. However, many individual equities remain under-owned, underfollowed, and structurally discounted. This combination is precisely what institutional investors tend to seek ahead of a major market regime shift.

Not all companies will benefit equally from uplisting. The primary beneficiaries are likely to be large, vertically integrated MSOs with strong compliance records, operational scale, and positive or near-positive cash flow. These companies are best positioned to meet exchange requirements and attract institutional capital. Secondary beneficiaries may include ancillary businesses that support the ecosystem, including investor relations firms, compliance platforms, and data infrastructure providers. Companies with weak balance sheets, fragmented operations, or regulatory exposure may struggle to qualify or fully participate in the upside.

While the opportunity is significant, investors should remain mindful of execution risk. Legislative timelines are uncertain, and even if H.R. 7987 advances, the details of implementation will matter. Market participants will closely evaluate which companies qualify, how quickly exchanges adapt, and whether broader reforms—such as federal rescheduling or banking legislation—follow.

Ultimately, H.R. 7987 does not legalize cannabis at the federal level, but it addresses one of the most critical barriers facing the industry: access to capital. By enabling uplisting, it effectively legitimizes cannabis equities within U.S. financial markets. That shift has the potential to unlock institutional adoption, lower the cost of capital, accelerate industry consolidation, and drive meaningful valuation expansion.

If realized, uplisting could represent one of the most significant inflection points in the history of U.S. cannabis equities. This is not merely a policy development. It is a fundamental transformation of how capital flows into the sector—and the market may not be fully pricing it in yet.